<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02891915</url>
  </required_header>
  <id_info>
    <org_study_id>14-0079</org_study_id>
    <secondary_id>HHSN272201300023I</secondary_id>
    <nct_id>NCT02891915</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children</brief_title>
  <official_title>A Phase IV Double-Blind, Placebo-Controlled, Randomized Trial to Evaluate Short Course vs.Standard Course Outpatient Therapy of Community Acquired Pneumonia in Children (SCOUT-CAP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, placebo-controlled, superiority clinical&#xD;
      trial will test the effectiveness of short (5-day) vs.standard (10-day) course therapy in&#xD;
      children who are diagnosed with CAP and initially treated in outpatient clinics, urgent care&#xD;
      facilities, and emergency departments. Primary objective is to compare the composite overall&#xD;
      outcome (Desirability of Outcome Ranking, DOOR) among children 6-71 months of age with CAP&#xD;
      assigned to a strategy of short course (5 days) vs standard course (10 days) outpatient&#xD;
      beta-lactam therapy at Outcome Assessment Visit #1 (Study Day 8 +/- 2 days)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, double-blind, placebo-controlled, superiority clinical&#xD;
      trial evaluating short course (5 day) vs. standard course (10 day) of oral beta-lactam&#xD;
      antibiotic therapy (amoxicillin, amoxicillin-clavulanate, cefdinir) for treatment of CAP in&#xD;
      children 6-71 months of age who have clinically improved prior to enrollment. The study will&#xD;
      randomize approximately 400 enrolled subjects to one of the two study arms (approximately 200&#xD;
      children in each arm) in order to reach 360 subjects completing Outcome Assessment Visit 1.&#xD;
      Subjects will be randomized (1:1) to receive either a standard course of the initially&#xD;
      prescribed antibiotic (10 days) or a short course of the initially prescribed antibiotic (5&#xD;
      days) plus 5 days of matching placebo. The study will recruit potential subjects from&#xD;
      children who are diagnosed with CAP and who are initiated on oral beta-lactam therapy by&#xD;
      healthcare providers in EDs, outpatient clinics, and urgent care centers at the study sites.&#xD;
      Day -5 is defined as the date on which oral beta-lactam therapy is initiated for a diagnosis&#xD;
      of CAP. Potential subjects will be identified at any time following clinical diagnosis of&#xD;
      pneumonia. These subjects will be assessed for eligibility and enrolled on Day -3 to -1 of&#xD;
      their initially prescribed oral beta-lactam therapy. Subjects may also be enrolled on Day 1&#xD;
      (the first day of receipt of study agent) provided they have not yet received any doses of&#xD;
      the healthcare provider-prescribed antibiotic therapy for that day. The Primary objective is&#xD;
      to compare the composite overall outcome (Desirability of Outcome Ranking, DOOR) among&#xD;
      children 6-71 months of age with CAP assigned to a strategy of short course (5 days) vs&#xD;
      standard course (10 days) outpatient beta-lactam therapy at Outcome Assessment Visit #1&#xD;
      (Study Day 8 +/- 2 days). The Secondary objectives are: 1) To compare the composite overall&#xD;
      outcome (DOOR) among children 6-71 months of age with CAP assigned to a strategy of short&#xD;
      course (5 days) vs standard course (10 days) outpatient beta-lactam therapy at Outcome&#xD;
      Assessment Visit #2 (Study Day 22 +/- 3 days); 2) To compare the resolution of symptoms (a&#xD;
      component of DOOR) among children 6-71 months of age with CAP assigned to a strategy of short&#xD;
      course (5 days) vs standard course (10 days) outpatient beta-lactam therapy at Outcome&#xD;
      Assessment Visits #1 and #2; 3) To compare the clinical response (a component of DOOR) among&#xD;
      children 6-71 months of age with CAP assigned to a strategy of short course (5 days) vs&#xD;
      standard course (10 days) outpatient beta-lactam therapy at Outcome Assessment Visits #1 and&#xD;
      #2; 4) To compare solicited events (a component of DOOR) among children 6-71 months of age&#xD;
      with CAP assigned to a strategy of short course (5 days) vs standard course (10 days)&#xD;
      outpatient beta-lactam therapy at Outcome Assessment Visits #1 and #2; 5) To compare&#xD;
      medically attended visits to Emergency Departments (ED) or outpatient clinics,&#xD;
      hospitalizations, surgical procedures, and receipt of non-study systemic antibiotics&#xD;
      (components of the clinical response) among children 6-71 months of age with CAP assigned to&#xD;
      a strategy of short course (5 days) vs standard course (10 days) outpatient beta-lactam&#xD;
      therapy at Outcome Assessment Visits #1 and #2&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2, 2016</start_date>
  <completion_date type="Actual">December 16, 2019</completion_date>
  <primary_completion_date type="Actual">December 16, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Desirability of Outcome Ranking (DOOR)</measure>
    <time_frame>Outcome Assessment Visit 1 (Study Day 8 +/- 2 days)</time_frame>
    <description>DOOR is a composite endpoint created using clinical outcomes from the first 5 days and at Outcome Assessment Visit #1 (OAV #1). It is based on adequate clinical response at OAV #1, solicited symptoms from first 5 days and number of days of antibiotics use for worsening pneumonia from the first 5 days of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Desirability of Outcome Ranking (DOOR)</measure>
    <time_frame>Outcome Assessment Visit 2 (Study Day 22 +/- 3 days)</time_frame>
    <description>DOOR is a composite endpoint created using clinical outcomes from the first 18 days and at Outcome Assessment Visit #2 (OAV #2). It is based on adequate clinical response at OAV #2, solicited symptoms from first 18 days and number of days of antibiotics use for worsening pneumonia from the first 18 days of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of Symptoms (a Component of DOOR)</measure>
    <time_frame>Outcome Assessment Visit 1 (Study Day 8 +/- 2 days)</time_frame>
    <description>This table provides number and percentage of subjects who experienced lack of resolution of symptoms by their OAV #1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of Symptoms (a Component of DOOR)</measure>
    <time_frame>Outcome Assessment Visit 2 (Study Day 22 +/- 3 days)</time_frame>
    <description>This table provides number and percentage of subjects who experienced lack of resolution of symptoms by their OAV #2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adequate Clinical Response Rates (a Component of DOOR)</measure>
    <time_frame>Outcome Assessment Visit 1 (Study Day 8 +/- 2 days)</time_frame>
    <description>Lack of adequate clinical response at OAV #1 is defined as the presence of a medically attended visit to an Emergency Department (ED) or outpatient clinic or hospitalization or receipt of non-study antibiotics or surgical procedures for persistent or worsening pneumonia from Day 1 to Day 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adequate Clinical Response Rates (a Component of DOOR)</measure>
    <time_frame>Outcome Assessment Visit 2 (Study Day 22 +/- 3 days)</time_frame>
    <description>Lack of adequate clinical response at OAV #2 is defined as the presence of a medically attended visit to an ED or outpatient clinic or hospitalization or receipt of non-study antibiotics or surgical procedures for persistent or worsening pneumonia from Day 1 to Day 18.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Solicited Symptoms</measure>
    <time_frame>Outcome Assessment Visit 1 (Study Day 8 +/- 2 days)</time_frame>
    <description>This table summarizes the number and percentage of subjects experiencing any solicited events of mild, moderate or severe severity from Day 1 to Day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Solicited Symptoms</measure>
    <time_frame>Outcome Assessment Visit 2 (Study Day 22 +/- 3 days)</time_frame>
    <description>This table summarizes the number and percentage of subjects experiencing any solicited events of mild, moderate or severe severity from Day 1 to Day 18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Receiving Non-study Systemic Antibiotics for Persistent or Worsening Pneumonia During Medically Attended Visits</measure>
    <time_frame>Outcome Assessment Visit 1 (Study Day 8 +/- 2 days)</time_frame>
    <description>This table provides number and percentage of subjects who received non-study antibiotics for any use from Day 1 to Day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Receiving Non-study Systemic Antibiotics for Persistent or Worsening Pneumonia During Medically Attended Visits</measure>
    <time_frame>Outcome Assessment Visit 2 (Study Day 22 +/- 3 days)</time_frame>
    <description>This table provides number and percentage of subjects who received non-study antibiotics for any use from Day 1 to Day 18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Receiving Non-study Systemic Antibiotics for All Causes During Medically Attended Visits</measure>
    <time_frame>Outcome Assessment Visit 1 (Study Day 8 +/- 2 days)</time_frame>
    <description>This table provides number and percentage of subjects who received non-study antibiotics for any reason from Day 1 to Day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Receiving Non-study Systemic Antibiotics for All Causes During Medically Attended Visits</measure>
    <time_frame>Outcome Assessment Visit 2 (Study Day 22 +/- 3 days)</time_frame>
    <description>This table provides number and percentage of subjects who received non-study antibiotics for any reason from Day 1 to Day 18</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">385</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Short</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 subjects will receive a short course of the initially prescribed antibiotic for 5 days plus 5 days of matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 subjects will receive a standard course of the initially prescribed antibiotic( Amoxicillin, Amoxicillin-Clavulanate, Cefdinir) for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Amoxicillin is an aminopenicillin antibiotic</description>
    <arm_group_label>Short</arm_group_label>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin-clavulanate</intervention_name>
    <description>A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.</description>
    <arm_group_label>Short</arm_group_label>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefdinir</intervention_name>
    <description>Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.</description>
    <arm_group_label>Short</arm_group_label>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Short</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 6 - 71 months&#xD;
&#xD;
          2. Provider diagnosis of CAP and prescription of antibiotic therapy with amoxicillin,&#xD;
             amoxicillin-clavulanate, or cefdinir&#xD;
&#xD;
             - amoxicillin or amoxicillin-clavulanate prescribed at a amoxicillin dose of 60&#xD;
             mg/kg/day&#xD;
&#xD;
             -- cefdinir prescribed at a minimum dose of 10 mg/kg/day&#xD;
&#xD;
          3. Parental report of clinical improvement&#xD;
&#xD;
             - based on lack of either subjective or known fever temperature &gt;/= 38.3Â°C in the&#xD;
             preceding 24 hours; current respiratory rate no greater than 50 breaths/minute (&lt;2&#xD;
             years of age) or breaths/minute (= / &gt; 2 years of age); and current grade of cough &lt; 3&#xD;
&#xD;
          4. Ability of a parent or guardian to understand and comply with the study procedures and&#xD;
             be available for all study visits&#xD;
&#xD;
          5. Signed written informed consent by a parent or guardian&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Treatment with any systemic antibiotic therapy within 7 days before the diagnosis of CAP&#xD;
        2. Initial therapy for CAP with combination antibiotic therapy&#xD;
&#xD;
          -  amoxicillin, amoxicillin/clavulanate or cefdinir plus one or more additional oral,&#xD;
             intravenous, or intramuscular antibiotics 3. History of anaphylaxis or severe drug&#xD;
             allergy to amoxicillin, if prescribed amoxicillin or amoxicillin/clavulanic acid; or&#xD;
             oral cephalosporin antibiotics (except cefaclor), if prescribed cefdinir 4. Presence&#xD;
             of concomitant bacterial infection that requires &gt; 5 days of antibiotic therapy 5.&#xD;
             Radiographic findings (where applicable) of complicated pneumonia at presentation or&#xD;
             any subsequent chest radiograph up to the time of enrollment&#xD;
&#xD;
          -  clinically significant pleural effusion, lung abscess, or pneumatocele 6.&#xD;
             Hospitalization for pneumonia during Day -5 to -1 of antibiotic therapy for CAP&#xD;
&#xD;
          -  subjects who require serial clinical assessments, but are discharged within 24 hours&#xD;
             will not be considered hospitalized and will not satisfy this exclusion criterion 7.&#xD;
             Pneumonia due to S. aureus or group A streptococcus documented by positive blood&#xD;
             culture or PCR, at the time of enrollment 8. History of pneumonia within the previous&#xD;
             6 months 9. History of persistent asthma within the previous 6 months or current acute&#xD;
             asthma exacerbation&#xD;
&#xD;
          -  persistent asthma is defined as receiving daily asthma maintenance therapy such as&#xD;
             inhaled corticosteroids, cromolyn, theophylline, or leukotriene receptor antagonists&#xD;
&#xD;
             -- acute asthma exacerbation is defined as receiving concomitant bronchodilator&#xD;
             therapy and systemic corticosteroids 10. Provider-diagnosis of aspiration pneumonia,&#xD;
             bronchiolitis, or bronchitis 11. Surgery or other invasive procedures of the upper or&#xD;
             lower airway (e.g., bronchoscopy, laryngoscopy) with general anesthesia or&#xD;
             hospitalization &lt;/=7 days before diagnosis of CAP 12. History of an underlying chronic&#xD;
             medical condition&#xD;
&#xD;
          -  including chronic heart disease, chronic lung disease (except asthma), congenital&#xD;
             anomalies of the airways or lung, cystic fibrosis, chronic renal disease including&#xD;
             nephrotic syndrome, protein-losing enteropathy of any cause, severe malnutrition,&#xD;
             neurocognitive disorders, metabolic disorders (including phenylketonuria), or genetic&#xD;
             disorders (note: genetic syndromes such as Down syndrome and Edwards Syndrome are&#xD;
             excluded; however, children with genetic disorders (e.g., hemophilia) but who do not&#xD;
             have a genetic syndrome may not satisfy this particular exclusion criterion; it is&#xD;
             important that children with such genetic disorders do not have symptoms and/or&#xD;
             comorbidities that would pose additional risk to them nor jeopardize the adequacy of&#xD;
             study assessments.) 13. History of a condition that compromises the immune system&#xD;
&#xD;
          -  HIV infection, primary immunodeficiency, anatomic or functional asplenia; receipt of a&#xD;
             hematopoietic stem cell or solid organ transplant at any time; receipt of&#xD;
             immunosuppressive therapy including chemotherapeutic agents, biologic agents,&#xD;
             antimetabolites or radiation therapy during the past 12 months; or daily use of&#xD;
             systemic corticosteroids for more than 7 consecutive days during the past 14 days 14.&#xD;
             Any other condition that in the judgment of the investigator precludes participation&#xD;
             because it could affect the safety of the subject 15. Current enrollment in another&#xD;
             clinical trial of an investigational agent 16. Previous enrollment in this trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>71 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama - Children's of Alabama - Infectious Diseases/Virology</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233-1711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital - Infectious Diseases</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202-3500</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville School of Medicine - Norton Children's Hospital - Infectious Diseases</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis - Infectious Diseases</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-1010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Human Vaccine Institute - Duke Vaccine and Trials Unit</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center - Infectious Diseases</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia - The Center for Pediatric Clinical Effectiveness</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-3309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC - General Academic Pediatric</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-3205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2573</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 5, 2017</verification_date>
  <study_first_submitted>September 1, 2016</study_first_submitted>
  <study_first_submitted_qc>September 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <results_first_submitted>December 10, 2020</results_first_submitted>
  <results_first_submitted_qc>January 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 3, 2021</results_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antimicrobial</keyword>
  <keyword>Beta-Lactam</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Short Course</keyword>
  <keyword>Standard Course</keyword>
  <keyword>Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Cefdinir</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02891915/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 24, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02891915/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Children, males and females, aged 6-71 months who are diagnosed with Community Acquired Pneumonia (CAP) and initially treated in outpatient clinics, urgent care facilities, and emergency departments were enrolled. Participants were enrolled between 02DEC2016 and 22NOV2019.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Short Course</title>
          <description>Participants will receive a short course of the initially prescribed antibiotic for 5 days plus 5 days of matching placebo&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="P2">
          <title>Standard Course</title>
          <description>Participants will receive a standard course of the initially prescribed antibiotic (Amoxicillin, Amoxicillin-Clavulanate, Cefdinir) for 10 days&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="192"/>
                <participants group_id="P2" count="193"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="179"/>
                <participants group_id="P2" count="181"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Enrolled but Treatment Not Administered</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Became Ineligible After Enrollment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Short Course</title>
          <description>Participants will receive a short course of the initially prescribed antibiotic for 5 days plus 5 days of matching placebo&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="B2">
          <title>Standard Course</title>
          <description>Participants will receive a standard course of the initially prescribed antibiotic( Amoxicillin, Amoxicillin-Clavulanate, Cefdinir) for 10 days&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="192"/>
            <count group_id="B2" value="193"/>
            <count group_id="B3" value="385"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.6" spread="16.6"/>
                    <measurement group_id="B2" value="36.8" spread="17.8"/>
                    <measurement group_id="B3" value="35.7" spread="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt; 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-71 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="190"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="173"/>
                    <measurement group_id="B3" value="349"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="239"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="192"/>
                    <measurement group_id="B2" value="193"/>
                    <measurement group_id="B3" value="385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <title>Arkansas Children's Hospital</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Children's Hospital of Philadelphia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Children's Hospital of Pittsburgh</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Cincinnati Children's Hospital</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Duke University</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>University of Alabama at Birmingham-Pediatrics</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Vanderbilt University Medical Center</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Washington University</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Initial Antibiotic</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Amoxicillin</title>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="350"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Amoxicillin Clavulanate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Cefdinir</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Initial Site of Treatment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>ED</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Out-Patient/Urgent Care</title>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Desirability of Outcome Ranking (DOOR)</title>
        <description>DOOR is a composite endpoint created using clinical outcomes from the first 5 days and at Outcome Assessment Visit #1 (OAV #1). It is based on adequate clinical response at OAV #1, solicited symptoms from first 5 days and number of days of antibiotics use for worsening pneumonia from the first 5 days of the study.</description>
        <time_frame>Outcome Assessment Visit 1 (Study Day 8 +/- 2 days)</time_frame>
        <population>Intent to Treat (ITT) Population: All randomized subjects that were still eligible on Day 1 of the study. Analysis of DOOR will use all subjects in the ITT population. Subjects with missing values of DOOR will have their values imputed. However, summaries of observed ordinal clinical response values presented below are based on complete data without imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Short Course</title>
            <description>Participants will receive a short course of the initially prescribed antibiotic for 5 days plus 5 days of matching placebo&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Standard Course</title>
            <description>Participants will receive a standard course of the initially prescribed antibiotic (Amoxicillin, Amoxicillin-Clavulanate, Cefdinir) for 10 days&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Desirability of Outcome Ranking (DOOR)</title>
          <description>DOOR is a composite endpoint created using clinical outcomes from the first 5 days and at Outcome Assessment Visit #1 (OAV #1). It is based on adequate clinical response at OAV #1, solicited symptoms from first 5 days and number of days of antibiotics use for worsening pneumonia from the first 5 days of the study.</description>
          <population>Intent to Treat (ITT) Population: All randomized subjects that were still eligible on Day 1 of the study. Analysis of DOOR will use all subjects in the ITT population. Subjects with missing values of DOOR will have their values imputed. However, summaries of observed ordinal clinical response values presented below are based on complete data without imputation.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Adequate clinical response with resolution of symptoms and no adverse events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Adequate clinical response with resolution of symptoms and with mild adverse events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Adequate clinical response with resolution of symptoms and with moderate adverse events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Adequate clinical response with resolution of symptoms and with severe adverse events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Adequate clinical response with persistent symptoms of fever, tachypnea, or cough</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lack of adequate clinical response with ED/clinic visit but no hospitalization</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lack of adequate clinical response with hospitalization</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Death from any cause</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null: the sum of the probability that a subject assigned to the 5-day arm will have a higher DOOR (higher DOOR is a lower value and is superior) than if assigned to the 10-day arm plus one-half the probability of equal DOORs is 50% (i.e., no difference in DOOR).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>DOOR is a composite endpoint created using clinical outcomes from the first 5 days and at Outcome Assessment Visit #1 (OAV #1). It is based on adequate clinical response at OAV #1, solicited symptoms from first 5 days and number of days of antibiotics use for worsening pneumonia from the first 5 days of the study.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Missing DOOR values at OAV #1 were first imputed using linear regression using baseline covariates and available DOOR components as covariates.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>The Mann-Whitney test was run on the multiple imputed datasets to generate estimates of DOOR probability and p-value</method_desc>
            <param_type>Pr (Higher DOOR in Short-Course)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Desirability of Outcome Ranking (DOOR)</title>
        <description>DOOR is a composite endpoint created using clinical outcomes from the first 18 days and at Outcome Assessment Visit #2 (OAV #2). It is based on adequate clinical response at OAV #2, solicited symptoms from first 18 days and number of days of antibiotics use for worsening pneumonia from the first 18 days of the study.</description>
        <time_frame>Outcome Assessment Visit 2 (Study Day 22 +/- 3 days)</time_frame>
        <population>ITT Population: All randomized subjects that were still eligible on Day 1 of the study. Analysis of DOOR will use all subjects in the ITT population. Subjects with missing values of DOOR will have their values imputed. However, summaries of observed ordinal clinical response values presented below are based on complete data without imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Short Course</title>
            <description>Participants will receive a short course of the initially prescribed antibiotic for 5 days plus 5 days of matching placebo&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Standard Course</title>
            <description>Participants will receive a standard course of the initially prescribed antibiotic (Amoxicillin, Amoxicillin-Clavulanate, Cefdinir) for 10 days&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Desirability of Outcome Ranking (DOOR)</title>
          <description>DOOR is a composite endpoint created using clinical outcomes from the first 18 days and at Outcome Assessment Visit #2 (OAV #2). It is based on adequate clinical response at OAV #2, solicited symptoms from first 18 days and number of days of antibiotics use for worsening pneumonia from the first 18 days of the study.</description>
          <population>ITT Population: All randomized subjects that were still eligible on Day 1 of the study. Analysis of DOOR will use all subjects in the ITT population. Subjects with missing values of DOOR will have their values imputed. However, summaries of observed ordinal clinical response values presented below are based on complete data without imputation.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Adequate clinical response with resolution of symptoms and no solicited events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Adequate clinical response with resolution of symptoms and with mild solicited events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Adequate clinical response with resolution of symptoms and with moderate solicited events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Adequate clinical response with resolution of symptoms and with severe solicited events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Adequate clinical response with persistent symptoms of fever, tachypnea, or cough</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lack of adequate clinical response with ED/clinic visit but no hospitalization</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Lack of adequate clinical response with hospitalization</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Death from any cause</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null: the sum of the probability that a subject assigned to the 5-day arm will have a higher DOOR (higher DOOR is a lower numerical value and is superior) than if assigned to the 10-day arm plus one-half the probability of equal DOORs is 50% (i.e., no difference in DOOR).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Testing whether Short course is superior to Standard course based on DOOR at OAV #2</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Missing DOOR values at OAV #2 were first imputed using linear regression using baseline covariates and available DOOR components as covariates</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>The Mann-Whitney test was run on the multiple imputed datasets to generate estimates of DOOR probability and p-value.</method_desc>
            <param_type>Pr (Higher DOOR in Short-Course)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>0.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resolution of Symptoms (a Component of DOOR)</title>
        <description>This table provides number and percentage of subjects who experienced lack of resolution of symptoms by their OAV #1.</description>
        <time_frame>Outcome Assessment Visit 1 (Study Day 8 +/- 2 days)</time_frame>
        <population>Complete Case at OAV #1. This population is made of subjects who were treated with at least one dose of study product, did not terminate early from the study before OAV #1, and completed OAV #1 with non-missing data for all DOOR components at OAV #1.</population>
        <group_list>
          <group group_id="O1">
            <title>Short Course</title>
            <description>Participants will receive a short course of the initially prescribed antibiotic for 5 days plus 5 days of matching placebo&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Standard Course</title>
            <description>Participants will receive a standard course of the initially prescribed antibiotic (Amoxicillin, Amoxicillin-Clavulanate, Cefdinir) for 10 days&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Resolution of Symptoms (a Component of DOOR)</title>
          <description>This table provides number and percentage of subjects who experienced lack of resolution of symptoms by their OAV #1.</description>
          <population>Complete Case at OAV #1. This population is made of subjects who were treated with at least one dose of study product, did not terminate early from the study before OAV #1, and completed OAV #1 with non-missing data for all DOOR components at OAV #1.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lack of Resolution of Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated respiratory rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resolution of Symptoms (a Component of DOOR)</title>
        <description>This table provides number and percentage of subjects who experienced lack of resolution of symptoms by their OAV #2.</description>
        <time_frame>Outcome Assessment Visit 2 (Study Day 22 +/- 3 days)</time_frame>
        <population>Complete Case at OAV #2. This population is made of subjects who were treated with at least one dose of study product, did not terminate early from the study before OAV #2, and completed OAV #2 with non-missing data for all DOOR components at OAV #2.</population>
        <group_list>
          <group group_id="O1">
            <title>Short Course</title>
            <description>Participants will receive a short course of the initially prescribed antibiotic for 5 days plus 5 days of matching placebo&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Standard Course</title>
            <description>Participants will receive a standard course of the initially prescribed antibiotic (Amoxicillin, Amoxicillin-Clavulanate, Cefdinir) for 10 days&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Resolution of Symptoms (a Component of DOOR)</title>
          <description>This table provides number and percentage of subjects who experienced lack of resolution of symptoms by their OAV #2.</description>
          <population>Complete Case at OAV #2. This population is made of subjects who were treated with at least one dose of study product, did not terminate early from the study before OAV #2, and completed OAV #2 with non-missing data for all DOOR components at OAV #2.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lack of Resolution of Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated respiratory rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adequate Clinical Response Rates (a Component of DOOR)</title>
        <description>Lack of adequate clinical response at OAV #1 is defined as the presence of a medically attended visit to an Emergency Department (ED) or outpatient clinic or hospitalization or receipt of non-study antibiotics or surgical procedures for persistent or worsening pneumonia from Day 1 to Day 5.</description>
        <time_frame>Outcome Assessment Visit 1 (Study Day 8 +/- 2 days)</time_frame>
        <population>Complete Case at OAV #1. This population is made of subjects who were treated with at least one dose of study product, did not terminate early from the study before OAV #1, and completed OAV #1 with non-missing data for all DOOR components at OAV #1.</population>
        <group_list>
          <group group_id="O1">
            <title>Short Course</title>
            <description>Participants will receive a short course of the initially prescribed antibiotic for 5 days plus 5 days of matching placebo&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Standard Course</title>
            <description>Participants will receive a standard course of the initially prescribed antibiotic (Amoxicillin, Amoxicillin-Clavulanate, Cefdinir) for 10 days&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Adequate Clinical Response Rates (a Component of DOOR)</title>
          <description>Lack of adequate clinical response at OAV #1 is defined as the presence of a medically attended visit to an Emergency Department (ED) or outpatient clinic or hospitalization or receipt of non-study antibiotics or surgical procedures for persistent or worsening pneumonia from Day 1 to Day 5.</description>
          <population>Complete Case at OAV #1. This population is made of subjects who were treated with at least one dose of study product, did not terminate early from the study before OAV #1, and completed OAV #1 with non-missing data for all DOOR components at OAV #1.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lack of Adequate Clinical Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ED or Clinic Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Receipt of Non-Study Antibiotic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adequate Clinical Response Rates (a Component of DOOR)</title>
        <description>Lack of adequate clinical response at OAV #2 is defined as the presence of a medically attended visit to an ED or outpatient clinic or hospitalization or receipt of non-study antibiotics or surgical procedures for persistent or worsening pneumonia from Day 1 to Day 18.</description>
        <time_frame>Outcome Assessment Visit 2 (Study Day 22 +/- 3 days)</time_frame>
        <population>Complete Case at OAV #2. This population is made of subjects who were treated with at least one dose of study product, did not terminate early from the study before OAV #2, and completed OAV #2 with non-missing data for all DOOR components at OAV #2.</population>
        <group_list>
          <group group_id="O1">
            <title>Short Course</title>
            <description>Participants will receive a short course of the initially prescribed antibiotic for 5 days plus 5 days of matching placebo&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Standard Course</title>
            <description>Participants will receive a standard course of the initially prescribed antibiotic (Amoxicillin, Amoxicillin-Clavulanate, Cefdinir) for 10 days&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Adequate Clinical Response Rates (a Component of DOOR)</title>
          <description>Lack of adequate clinical response at OAV #2 is defined as the presence of a medically attended visit to an ED or outpatient clinic or hospitalization or receipt of non-study antibiotics or surgical procedures for persistent or worsening pneumonia from Day 1 to Day 18.</description>
          <population>Complete Case at OAV #2. This population is made of subjects who were treated with at least one dose of study product, did not terminate early from the study before OAV #2, and completed OAV #2 with non-missing data for all DOOR components at OAV #2.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lack of Adequate Clinical Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ED or Clinic Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Receipt of Non-Study Antibiotic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Solicited Symptoms</title>
        <description>This table summarizes the number and percentage of subjects experiencing any solicited events of mild, moderate or severe severity from Day 1 to Day 5</description>
        <time_frame>Outcome Assessment Visit 1 (Study Day 8 +/- 2 days)</time_frame>
        <population>Complete Case at OAV #1. This population is made of subjects who were treated with at least one dose of study product, did not terminate early from the study before OAV #1, and completed OAV #1 with non-missing data for all DOOR components at OAV #1.</population>
        <group_list>
          <group group_id="O1">
            <title>Short Course</title>
            <description>Participants will receive a short course of the initially prescribed antibiotic for 5 days plus 5 days of matching placebo&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Standard Course</title>
            <description>Participants will receive a standard course of the initially prescribed antibiotic (Amoxicillin, Amoxicillin-Clavulanate, Cefdinir) for 10 days&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Symptoms</title>
          <description>This table summarizes the number and percentage of subjects experiencing any solicited events of mild, moderate or severe severity from Day 1 to Day 5</description>
          <population>Complete Case at OAV #1. This population is made of subjects who were treated with at least one dose of study product, did not terminate early from the study before OAV #1, and completed OAV #1 with non-missing data for all DOOR components at OAV #1.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allergic Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stomatitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Candidiasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Solicited Symptoms</title>
        <description>This table summarizes the number and percentage of subjects experiencing any solicited events of mild, moderate or severe severity from Day 1 to Day 18</description>
        <time_frame>Outcome Assessment Visit 2 (Study Day 22 +/- 3 days)</time_frame>
        <population>Complete Case at OAV #2. This population is made of subjects who were treated with at least one dose of study product, did not terminate early from the study before OAV #2, and completed OAV #2 with non-missing data for all DOOR components at OAV #2.</population>
        <group_list>
          <group group_id="O1">
            <title>Short Course</title>
            <description>Participants will receive a short course of the initially prescribed antibiotic for 5 days plus 5 days of matching placebo&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Standard Course</title>
            <description>Participants will receive a standard course of the initially prescribed antibiotic (Amoxicillin, Amoxicillin-Clavulanate, Cefdinir) for 10 days&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Symptoms</title>
          <description>This table summarizes the number and percentage of subjects experiencing any solicited events of mild, moderate or severe severity from Day 1 to Day 18</description>
          <population>Complete Case at OAV #2. This population is made of subjects who were treated with at least one dose of study product, did not terminate early from the study before OAV #2, and completed OAV #2 with non-missing data for all DOOR components at OAV #2.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allergic Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stomatitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Candidiasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Receiving Non-study Systemic Antibiotics for Persistent or Worsening Pneumonia During Medically Attended Visits</title>
        <description>This table provides number and percentage of subjects who received non-study antibiotics for any use from Day 1 to Day 5</description>
        <time_frame>Outcome Assessment Visit 1 (Study Day 8 +/- 2 days)</time_frame>
        <population>Complete Case at OAV #1. This population is made of subjects who were treated with at least one dose of study product, did not terminate early from the study before OAV #1, and completed OAV #1 with non-missing data for all DOOR components at OAV #1.</population>
        <group_list>
          <group group_id="O1">
            <title>Short Course</title>
            <description>Participants will receive a short course of the initially prescribed antibiotic for 5 days plus 5 days of matching placebo&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Standard Course</title>
            <description>Participants will receive a standard course of the initially prescribed antibiotic (Amoxicillin, Amoxicillin-Clavulanate, Cefdinir) for 10 days&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Receiving Non-study Systemic Antibiotics for Persistent or Worsening Pneumonia During Medically Attended Visits</title>
          <description>This table provides number and percentage of subjects who received non-study antibiotics for any use from Day 1 to Day 5</description>
          <population>Complete Case at OAV #1. This population is made of subjects who were treated with at least one dose of study product, did not terminate early from the study before OAV #1, and completed OAV #1 with non-missing data for all DOOR components at OAV #1.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ED or Clinic Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Receipt of Non-Study Antibiotic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Receiving Non-study Systemic Antibiotics for Persistent or Worsening Pneumonia During Medically Attended Visits</title>
        <description>This table provides number and percentage of subjects who received non-study antibiotics for any use from Day 1 to Day 18</description>
        <time_frame>Outcome Assessment Visit 2 (Study Day 22 +/- 3 days)</time_frame>
        <population>Complete Case at OAV #2. This population is made of subjects who were treated with at least one dose of study product, did not terminate early from the study before OAV #2, and completed OAV #2 with non-missing data for all DOOR components at OAV #2.</population>
        <group_list>
          <group group_id="O1">
            <title>Short Course</title>
            <description>Participants will receive a short course of the initially prescribed antibiotic for 5 days plus 5 days of matching placebo&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Standard Course</title>
            <description>Participants will receive a standard course of the initially prescribed antibiotic (Amoxicillin, Amoxicillin-Clavulanate, Cefdinir) for 10 days&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Receiving Non-study Systemic Antibiotics for Persistent or Worsening Pneumonia During Medically Attended Visits</title>
          <description>This table provides number and percentage of subjects who received non-study antibiotics for any use from Day 1 to Day 18</description>
          <population>Complete Case at OAV #2. This population is made of subjects who were treated with at least one dose of study product, did not terminate early from the study before OAV #2, and completed OAV #2 with non-missing data for all DOOR components at OAV #2.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ED or Clinic Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Receipt of Non-Study Antibiotic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Receiving Non-study Systemic Antibiotics for All Causes During Medically Attended Visits</title>
        <description>This table provides number and percentage of subjects who received non-study antibiotics for any reason from Day 1 to Day 5</description>
        <time_frame>Outcome Assessment Visit 1 (Study Day 8 +/- 2 days)</time_frame>
        <population>Complete Case at OAV #1. This population is made of subjects who were treated with at least one dose of study product, did not terminate early from the study before OAV #1, and completed OAV #1 with non-missing data for all DOOR components at OAV #1.</population>
        <group_list>
          <group group_id="O1">
            <title>Short Course</title>
            <description>Participants will receive a short course of the initially prescribed antibiotic for 5 days plus 5 days of matching placebo&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Standard Course</title>
            <description>Participants will receive a standard course of the initially prescribed antibiotic (Amoxicillin, Amoxicillin-Clavulanate, Cefdinir) for 10 days&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Receiving Non-study Systemic Antibiotics for All Causes During Medically Attended Visits</title>
          <description>This table provides number and percentage of subjects who received non-study antibiotics for any reason from Day 1 to Day 5</description>
          <population>Complete Case at OAV #1. This population is made of subjects who were treated with at least one dose of study product, did not terminate early from the study before OAV #1, and completed OAV #1 with non-missing data for all DOOR components at OAV #1.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ED or Clinic Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Receipt of Non-Study Antibiotic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Receiving Non-study Systemic Antibiotics for All Causes During Medically Attended Visits</title>
        <description>This table provides number and percentage of subjects who received non-study antibiotics for any reason from Day 1 to Day 18</description>
        <time_frame>Outcome Assessment Visit 2 (Study Day 22 +/- 3 days)</time_frame>
        <population>Complete Case at OAV #2. This population is made of subjects who were treated with at least one dose of study product, did not terminate early from the study before OAV #2, and completed OAV #2 with non-missing data for all DOOR components at OAV #2.</population>
        <group_list>
          <group group_id="O1">
            <title>Short Course</title>
            <description>Participants will receive a short course of the initially prescribed antibiotic for 5 days plus 5 days of matching placebo&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Standard Course</title>
            <description>Participants will receive a standard course of the initially prescribed antibiotic (Amoxicillin, Amoxicillin-Clavulanate, Cefdinir) for 10 days&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Receiving Non-study Systemic Antibiotics for All Causes During Medically Attended Visits</title>
          <description>This table provides number and percentage of subjects who received non-study antibiotics for any reason from Day 1 to Day 18</description>
          <population>Complete Case at OAV #2. This population is made of subjects who were treated with at least one dose of study product, did not terminate early from the study before OAV #2, and completed OAV #2 with non-missing data for all DOOR components at OAV #2.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ED or Clinic Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Receipt of Non-Study Antibiotic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events (AEs) that occurred from Receipt of Study Agent (Day 1) through the final Outcome Assessment Visit (Day 22 +/- 3 days) were reported.</time_frame>
      <desc>Solicited AEs for both the Short and Standard course were assessed using MedDRA 22.0.</desc>
      <group_list>
        <group group_id="E1">
          <title>Short Course</title>
          <description>Participants will receive a short course of the initially prescribed antibiotic for 5 days plus 5 days of matching placebo&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="E2">
          <title>Standard Course</title>
          <description>Participants will receive a standard course of the initially prescribed antibiotic (Amoxicillin, Amoxicillin-Clavulanate, Cefdinir) for 10 days&#xD;
Amoxicillin: Amoxicillin is an aminopenicillin antibiotic&#xD;
Amoxicillin-clavulanate: A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.&#xD;
Cefdinir: Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA V22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="41" subjects_affected="23" subjects_at_risk="192"/>
                <counts group_id="E2" events="62" subjects_affected="28" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="124" subjects_affected="37" subjects_at_risk="192"/>
                <counts group_id="E2" events="125" subjects_affected="34" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="370" subjects_affected="73" subjects_at_risk="192"/>
                <counts group_id="E2" events="313" subjects_affected="65" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" events="98" subjects_affected="22" subjects_at_risk="192"/>
                <counts group_id="E2" events="156" subjects_affected="23" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. C. Buddy Creech</name_or_title>
      <organization>Vanderbilt Vaccine Research Program</organization>
      <phone>615-343-0332</phone>
      <email>buddy.creech@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

